Navigation Links
IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
Date:1/11/2010

WESTBROOK, Maine, Jan. 11 /PRNewswire-FirstCall/ -- IDEXX Laboratories, Inc. (Nasdaq: IDXX), announced today that it placed in excess of 2,000 Catalyst Dx® chemistry analyzers in 2009, bringing the installed base to nearly 2,800. Catalyst Dx, introduced in the first quarter of 2008, is a next generation chemistry instrument that adds to the IDEXX VetLab® integrated suite of analyzers and significantly expands the range and capability of the veterinary practice's in-house diagnostic laboratory.

The Company also announced that its installed base of IDEXX SmartService(TM) customers had grown to over 2,000. SmartService provides veterinary practices using the IDEXX VetLab suite of instruments with proactive, secure service and support over the Internet, reducing potential instrument downtime while improving practice work flow.

"We are very pleased with the strength of our Catalyst Dx placements during the fourth quarter, which exceeded our expectations from October," said Jonathan Ayers, Chief Executive Officer. "We also are excited about the growth in SmartService installations, as SmartService allows us to provide better and faster service and updates to our IDEXX VetLab customers. Both Catalyst Dx and SmartService support our objective to provide products and services that help veterinary practices offer a higher standard of care and improve their businesses."

As previously announced, IDEXX Laboratories is participating in the J.P. Morgan 28th Annual Healthcare Conference in San Francisco, California and will be making a presentation today about the business, including the items disclosed in this press release.

About IDEXX Laboratories

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,700 people and offers products to customers in over 100 countries.

Contact: Merilee Raines, Investor Relations, (207) 556-8155

SOURCE IDEXX Laboratories, Inc.

RELATED LINKS
http://www.idexx.com

'/>"/>

SOURCE IDEXX Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaron Expands Portfolio of Services with Acquisition of Bridge Laboratories China
2. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
3. Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection
4. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
5. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
7. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
8. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
9. MO BIO Laboratories, Inc. Launches LifeGuard(TM) Soil Preservation Solution
10. Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast
11. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology:
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):